medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2016, Número 4

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2016; 32 (4)


Síndromes mielodisplásicos: una mirada al último decenio

Fernández DND

Idioma: Español
Referencias bibliográficas: 54
Paginas: 423-437
Archivo PDF: 150.75 Kb.


RESUMEN

Los síndromes mielodisplásicos, ahora denominados por la Organización Mundial de la Salud como neoplasias mieloides, han sufrido grandes cambios en los últimos años. Se han identificado nuevos elementos en su fisiopatología con influencia en el diagnóstico, pronóstico y terapéutica de estos pacientes. Múltiples y profundos descubrimientos han ocurrido en la biología molecular, la citogenética y el inmunofenotipajede la enfermedad, que sientan las bases para nuevas terapéuticas, ya en investigación. En este artículo se realiza un resumen de los principales acontecimientos ocurridos en la última década.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification ofmyeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.

  2. Greenberg PL, Tuechler H, SchanzJ, Sanz G, García-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454-65.

  3. Gangat N, Patnaik MM, Begna K, Taxiarchis K, Kali AA, Elliot M, et al. Primary Myelodysplastic Syndromes. The mayo Clinic Experience with 1000 patients. Mayo Clin Proc. 2015 Dec;90(12):1623-38. doi: 10.1016/j.mayocp.2015.08.022

  4. Greenberg PL. Current therapeutic approaches for patients with myelodysplasticsindromes. Br JHaematol. 2010;150:131-43.

  5. Bulycheva E, Rauner M, Medyouf H, Theurl I, Bornhäuser M, Hofbauer LC, et al. Myelodysplasia is the niche: novel concepts and emerging therapies. Leukemia. 2015;29:259-68.

  6. García-Manero GM. Myelodysplastic Syndromes:2014 update on diagnosis, risks stratification and management. Am J Hematol. 2014;89(1):97-108.

  7. Solé F. Nueva clasificación pronóstica de las anomalías cromosómicas para los SMD. Haematologica/edición española. 2010;95 (extra1):290-4.

  8. Schanz J, Tüchler H, Sole F, Mallo M, Lunõ E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplasticsyndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012 30:820-29.

  9. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, et al. Myelodysplastic Syndromes: clinical practice guidelines in oncology. JNatlComprCancNetw. 2013 Jul;11(7):838-74.

  10. Haase P, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the kariotipe in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.

  11. Papaemmanuil E, Gerstung M, MalcovatiL,Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-27.

  12. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569-72.

  13. Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, KrauterJ, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578-84.

  14. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk Myelodysplastic Syndromes. J Clin Oncol. 2012;30:3376-82.

  15. Abdel-Wahab O, Levine RL. Mutationes epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013;121:3563-72.

  16. Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, et al . MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126(21):2355-61.

  17. Cervera J, Such E, Valencia A, Ibañez M, Luna I, Gómez I, et al. Contribución de las nuevas técnicas de análisis genéticos al conocimientode la patogénesis de los Síndromes Mielodisplásicos. Haematologica/edición española. 2010;95 (extra1):285-90.

  18. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, TrainaF, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012;120(16):3173-86.

  19. Nikpour M, Pellagatti A, Liu A, Karimi M, Malcovati L, Gogvadze V, et al. Gene expression profiling of erythroblasts from refractory anaeemia with ring sideroblasts (RARS) and effects of G-CSF. Br J Haematol.2010;149(6):844-54.

  20. Boultwood J, Pellagatti A, MacKenzie ANJ, Wainscot JS. Advances in the 5q syndrome. Blood. 2010;116(26):5803-11.

  21. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, et al. TP53 Mutations in low-risk Myelodysplastic Syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29:1971-79.

  22. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature Medicine. 2010;16(1):49-58.

  23. Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia Blood. 2015;125(7):1083-90.

  24. Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes andrelateddisorders. Blood. 2013;122(18):3169-77.

  25. Orfao A, Matarraz S, López A, Barreno S, Fernández C, Flores J, et al. Impacto de La citometría de flujo en el diagnóstico y pronóstico de los Síndromes mielodisplásicos. Haematologica/edición español. 2010;95(extra1):294-99.

  26. Xu F, Guo J, Wu LY, He Q, Zhang Z, Chang CK, et al. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes. Cytometry B Clin Cytom. 2013;84:267-78.

  27. Burbury KL, Westerman DA. Role of flow cytometry in myelodysplastic syndromes: diagnosis, classification, prognosis and response assessment. Leuk Lymphoma. 2014;55:749-60.

  28. Chung JW, Park CJ, Cha CH, Cho YU, Jang S, Chi HS, et al. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome. Ann Clin Lab Sci. 2012;42:271-80.

  29. Chopra A, Pati H, Mahapatra M, Mishra P, Seth T, Kumar S, et al. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation patternbased and quantitative approaches. Ann Hematol. 2012;91:1351-62.

  30. Porwit A, van de Loosdrecht AA, Bettelheim P, Eidenschink-Brodersen L, Burbury K, Cremers E, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplasticsyndromesproposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014; 28:1793-98.

  31. Greenberg PL, Cox C, Le Bau MM, Fenaux JM, Morel P, Sanz , et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.

  32. Lancet JE, Zhang L. Understanding the pathology of myelodysplastic syndrome to guide treatment CME. 2013. (citado: 29 de febrero 2016). Medscape Education Pathology. Disponible en: http://www.medscape.org/viewarticle/804883

  33. Mishra A, Corrales-Yepez M, Ali Nl, Kharfan-Dabaja M, Padron E, Zhang L, et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplasticsíndromes. Am J Hematol. 2013;88(7):566-70.

  34. Voso MT, Fenu S, Latagliata R, Buccisano E, Piciocchi A, Aloe-Spiriti MA, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplasticsyndromes significantly better than IPSS and WHO Prognostic Scoring System:validation by the GruppoRomano Mielodisplasie Italian Regional Database. J Clin Oncol. 2013;31(21):2671-7.

  35. Stone RM. How I treat patients with myelodysplasticsyndromes. Blood. 2009;113:6296-6303.

  36. Santini V. Clinical Use of Erythropoietic Stimulating Agents in Myelodysplastic Syndromes. Oncologist. 2011;16(suppl 3):35-42.

  37. Malcovati L, Hellströnm-Lindberg E, Bowen D, Adés L, Cermak J, del Caňizo C, et al. Diagnosis and treatment of primary myelodysplastic syndrome in adult: recommendations from European LeukemiaNet. Blood. 2013;122(17):2943-64.

  38. Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplatic syndromes. Hematology. 2008:166-75.

  39. Giagounidis A, Mufti GJ, Fenaux J, Sekeres MA, Szer J, Platzbecker U, et al. Results of a randomized, double-bind study of romiplostimverus placebo in patients with myelodysplastic syndromes and thrombocytopenia. Cancer. 2014;120(12):1838-46.

  40. Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0.

  41. Huzcschenreuter F, Monsef I, Kreuzer KA, Engert A, Skoetz N. Granulocite and granulocyte-macrophage colony stimulating factor for newly diagnosed patients with myelodysplastic syndrome. Cochrane Database Syst Rev. 2016 Feb 16;2:CD009310.

  42. Krönke J, Fink1 EC, Hollenbach PW, MacBethKJ,Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS. Nature. 2015;523:183-8

  43. Passweg JR, Giagounii AA, Simcock M, Aul C, Dobbelstein C, Stadler M, et al. Immunosupressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing nthytimocite globulin plus cyclosporine with best supportive care-SAKK 33/99. J ClinOncol. 2011;29(3):303-09.

  44. García-Manero G, Jabbour E, Burthakur,Faderl S, Estrov Z, Yang H, et al. Randomized open-label phase II study of decitabine in patients with low or intermediate riskmyelodysplastic syndromes. J Clin Oncol. 2013;31(20):2548-53. doi: 10.1200/JCO.2012.44.6823.

  45. Grinblatt DL, Sekeres MA, Komrokji R, Swern A, Sullivan KA, Narang M. Patients withmyelodysplastic syndrome treated wthazacitidine in clinical practice the AVIDA registry. Leuk Lymphoma. 2015;56(4):887-95.

  46. Bernal T, Martínez-Camblor P , Sánchez-García J , SanzG. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply. Leukemia. 2016 Mar;30(3):740-1. doi: 10.1038/leu.2015.339.

  47. Fraison JB, Mekinian A, Grignano E, Kahn JE, Arlet JB, Decaux O, et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res. 2016 Feb 20;43:13-17.

  48. Devillier R, Bramanti S, Fürst S, Sarina B, El-Cheikh J, Crocchiolo R, et al. Treplete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplant. 2016 Feb;51(2):194-8. doi: 10.1038/bmt.2015.270.

  49. Patnaik MM, Tefferi A. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clin Proc. 2016;91(2):259-72.

  50. Duong, Jaglal MV, Zhang L, Kalec V, Lancet JE, Komrokjib RS, et al. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leukemia Res. 2013;37:300-4.

  51. Komrokji RS, Raza A, Lancet JC, Ren C, Taft D, Maniar M, et al. Phase I clinical trial of oral Rigosertib in patients with myelodysplasticsyndromes. Br J Haematol. 2013;162(4):517-24.

  52. Komrokji RS, Padron E, Yu D, Fulp WJ, Rodríguez Y, Tinsley S, et al. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014;89(8):809-12

  53. Chamseddine AN, Jabbour E, Kantarjian HM, Bohannan ZS, Garcia-Manero G. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep. 2016 Jan;18(1):4. doi: 10.1007/s11912-015-0489.

  54. Kiyoi H. Overview: A New Era of Cancer Genome in Myeloid Malignancies. Oncology. 2015;89 (Suppl 1):1-3.




2020     |     www.medigraphic.com